Q-omics provides the consensus-scored RPL7P28 profile across patient tissues and cancer cell-line models. RPL7P28 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL7P28 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, RPL7P28 RNA expression shows 13,859 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, LUSC, and THYM as cancer lineages where RPL7P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P28 survival associations across molecular data types. RPL7P28 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P28 RNA expression–survival associations across cancer types. High RPL7P28 expression shows unfavorable associations in UVM, COAD and LIHC, but favorable associations in SKCM, BLCA and LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL7P28 RNA expression.
This table summarizes RPL7P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P28 shows higher tumor expression in LUSC, HNSC, STAD, CHOL, COAD and LUAD. The LUSC box plot shows higher RPL7P28 RNA expression in tumor versus normal tissue (log2 FC = +0.340, t-test p < 0.001).
This table shows molecular features associated with RPL7P28 in patient tissues and cancer cell lines. In patient samples, RPL7P28 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
